High-yield dividend stocks have been gaining momentum ahead of potential Fed rate cuts. Here's why these two high-yield ...

Wilson celebrates the first U.S. patient to complete gene therapy for sickle cell, but says advocacy must continue.

As we reported this morning, the deal gives Pfizer already-approved SCD therapy Oxbryta (voxelator) – which industry watchers reckon could see a dramatic uptick in sales with Pfizer's marketing ...

Andrew Fein, an analyst from H.C. Wainwright, reiterated the Hold rating on Fulcrum Therapeutics (FULC – Research Report). The associated ...

Biotech-stock investing has one tough test for success - and it's about to get easier ...

Skorney cited a drug called Oxbryta from Pfizer (PFE), which was approved to treat the blood disorder sickle cell. Instead of using clinical benefit as the benchmark, the FDA approved Oxbryta based on ...

Pfizer Inc. discovers, develops ... and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under ...

UBS analyst Trung Huynh maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $31.00. The company’s shares closed yesterday at $26.72. Huynh covers the ...

NEW YORK, November 14, 2024--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Andrew Baum, Chief Strategy and ...